journal article·2017-06-27

High-Speed Atomic Force Microscopy Reveals Loss of Nuclear Pore Resilience as a Dying Code in Colorectal Cancer Cells

Mahmoud Shaaban Mohamed, Akiko Kobayashi, Azuma Taoka, Takahiro Watanabe-Nakayama, Yosuke Kikuchi, Masaharu Hazawa, Toshinari Minamoto, Yoshihiro Fukumori, Noriyuki Kodera, Takayuki Uchihashi, Toshio Ando, Richard W. Wong

ACS Nano· Volume 11· Issue 6
Publisher page

Abstract

Nuclear pore complexes (NPCs) are the sole turnstile implanted in the nuclear envelope (NE), acting as a central nanoregulator of transport between the cytosol and the nucleus. NPCs consist of ∼30 proteins, termed nucleoporins. About one-third of nucleoporins harbor natively unstructured, intrinsically disordered phenylalanine-glycine strings (FG-Nups), which engage in transport selectivity. Because the barriers insert deeply in the NPC, they are nearly inaccessible. Several in vitro barrier models have been proposed; however, the dynamic FG-Nups protein molecules themselves are imperceptible in vivo. We show here that high-speed atomic force microscopy (HS-AFM) can be used to directly visualize nanotopographical changes of the nuclear pore inner channel in colorectal cancer (CRC) cells. Furthermore, using MLN8237/alisertib, an apoptotic and autophagic inducer currently being tested in relapsed cancer clinical trials, we unveiled the functional loss of nucleoporins, particularly the deformation of the FG-Nups barrier, in dying cancer cells. We propose that the loss of this nanoscopic resilience is an irreversible dying code in cells. These findings not only illuminate the potential application of HS-AFM as an intracellular nanoendoscopy but also might aid in the design of future nuclear targeted nanodrug delivery tailored to the individual patient.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nuclear Structure and Function · Force Microscopy Techniques and Applications · RNA Research and Splicing

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Cell-Bionomics Research Unit, Innovative Integrated Bio-Research Core, Institute for Frontier Science Initiative, ‡Bio-AFM Frontier Research Center, §Division of Natural System, School of Natural Science and Technology, and ∥Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan

Funding

Takeda Science Foundation · Sumitomo Foundation · Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care · Asahi Glass Foundation · Kowa Life Science Foundation · Japan Society for the Promotion of Science · Mochida Memorial Foundation for Medical and Pharmaceutical Research · Uehara Memorial Foundation · Suzuken Memorial Foundation · Sagawa Foundation · Cancer Research Institute, Kanazawa University

References (56)

Show source-provided references
1. 10.1007/s10555-011-9287-y10.1007/s10555-011-9287-y ↗
2. 10.1021/acsnano.5b0740610.1021/acsnano.5b07406 ↗
3. 10.1021/nn403329410.1021/nn4033294 ↗
4. 10.1016/j.chembiol.2015.10.00110.1016/j.chembiol.2015.10.001 ↗
5. 10.1126/science.aad729710.1126/science.aad7297 ↗
6. 10.1016/j.chembiol.2016.05.00410.1016/j.chembiol.2016.05.004 ↗
7. 10.1371/journal.pbio.100236510.1371/journal.pbio.1002365 ↗
8. 10.1021/nn500857210.1021/nn5008572 ↗
9. 10.1016/j.tcb.2003.10.00710.1016/j.tcb.2003.10.007 ↗
10. 10.1073/pnas.060352110310.1073/pnas.0603521103 ↗
11. 10.1016/j.cell.2012.07.01910.1016/j.cell.2012.07.019 ↗
12. 10.7554/eLife.1078510.7554/eLife.10785 ↗
13. 10.1074/mcp.M000035-MCP20110.1074/mcp.M000035-MCP201 ↗
14. 10.1021/nn900152m10.1021/nn900152m ↗
15. 10.1083/jcb.20080617310.1083/jcb.200806173 ↗
16. 10.1073/pnas.120048610910.1073/pnas.1200486109 ↗
17. 10.1038/nnano.2014.26210.1038/nnano.2014.262 ↗
18. 10.1016/j.jconrel.2016.11.00810.1016/j.jconrel.2016.11.008 ↗
19. 10.1073/pnas.080196710510.1073/pnas.0801967105 ↗
20. 10.1038/nnano.2016.7410.1038/nnano.2016.74 ↗
21. 10.1021/nl504478f10.1021/nl504478f ↗
22. 10.1016/j.sbi.2014.07.01110.1016/j.sbi.2014.07.011 ↗
23. 10.1021/cr400383710.1021/cr4003837 ↗
24. 10.1038/nprot.2012.04710.1038/nprot.2012.047 ↗
25. 10.1038/nnano.2016.6210.1038/nnano.2016.62 ↗
26. 10.1038/ncomms315510.1038/ncomms3155 ↗
27. 10.1073/pnas.21140089810.1073/pnas.211400898 ↗
28. 10.1038/srep0872410.1038/srep08724 ↗
29. 10.1007/s10616-012-9501-y10.1007/s10616-012-9501-y ↗
30. 10.1126/science.110480810.1126/science.1104808 ↗
31. 10.1038/nrm.2016.14710.1038/nrm.2016.147 ↗
32. 10.1073/pnas.162108511410.1073/pnas.1621085114 ↗
33. 10.1073/pnas.162029311410.1073/pnas.1620293114 ↗
34. 10.1111/j.1742-4658.2010.07982.x10.1111/j.1742-4658.2010.07982.x ↗
35. 10.1161/01.RES.0000059415.25070.5410.1161/01.RES.0000059415.25070.54 ↗
36. 10.1016/j.yjmcc.2016.01.02210.1016/j.yjmcc.2016.01.022 ↗
37. 10.18632/oncotarget.1036610.18632/oncotarget.10366 ↗
38. 10.1016/S1470-2045(15)70051-310.1016/S1470-2045(15)70051-3 ↗
39. 10.1158/1078-0432.CCR-11-153610.1158/1078-0432.CCR-11-1536 ↗
40. 10.1038/srep0087810.1038/srep00878 ↗
41. 10.1016/j.semcancer.2011.10.00510.1016/j.semcancer.2011.10.005 ↗
42. 10.1038/nature1554810.1038/nature15548 ↗
43. 10.1002/cphc.20080021010.1002/cphc.200800210 ↗
44. 10.1073/pnas.82.24.852710.1073/pnas.82.24.8527 ↗
45. 10.4161/nucl.1381810.4161/nucl.13818 ↗
46. 10.1016/j.cell.2007.07.02910.1016/j.cell.2007.07.029 ↗
47. 10.1016/j.tibs.2015.11.00110.1016/j.tibs.2015.11.001 ↗
48. 10.1073/pnas.050012710210.1073/pnas.0500127102 ↗
49. 10.1038/nrc321910.1038/nrc3219 ↗
50. 10.1007/978-1-4899-8032-8_1310.1007/978-1-4899-8032-8_13 ↗
51. 10.1038/sj.onc.120461110.1038/sj.onc.1204611 ↗
52. 10.1038/oncsis.2013.3510.1038/oncsis.2013.35 ↗
53. 10.1080/15384101.2015.102151810.1080/15384101.2015.1021518 ↗
54. 10.1038/cddis.2013.37010.1038/cddis.2013.370 ↗
55. 10.4161/cc.2667110.4161/cc.26671 ↗
56. 10.1074/jbc.M110.10589010.1074/jbc.M110.105890 ↗